Table 5.
Sensitivity analyses for numbers of cases of post-antibiotic vulvovaginitis in women taking oral and vaginal lactobacillus. Participants who did not give complete outcome data were either viewed as all non-cases, or those who reported symptoms or had unknown outcomes were viewed as cases
|
No (%) of women
|
|||
|---|---|---|---|
| Cases | Non-cases | Odds ratio (95% Cl)* | |
|
Scenario 1: Non-completers coded as non-cases
|
|
|
|
| Oral treatment: | |||
| Active
|
29 (21)
|
111(79)
|
1.14 (0.63 to 2.06) |
| Placebo | 26 (19) | 112 (81) | |
| Vaginal treatment: | |||
| Active
|
31 (23)
|
106 (77)
|
1.43 (0.79 to 2.59) |
| Placebo | 24 (17) | 117 (83) | |
|
Scenario 2: Non-completers with symptoms or unknown outcomes coded as cases
| |||
| Oral treatment: | |||
| Active
|
35 (25)
|
105 (75)
|
0.82 (0.48 to 1.40) |
| Placebo | 40 (29) | 98 (71) | |
| Vaginal treatment: | |||
| Active
|
41 (30)
|
96 (70)
|
1.34 (0.79 to 2.28) |
| Placebo | 34 (24) | 107 (76) | |
*
Odds ratio of active treatment v placebo calculated with logistic regression.